Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -41.58% is 109% below its 5-year average of -19.94%, near the low end of its 5-year range (-51.85%–2.08%).
74.05% below its 12-month average of -23.89%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.60%.
RETURN ON ASSETS (ROA)
-41.58%
RETURN ON ASSETS (ROA) AVG TTM
-23.89%
RETURN ON ASSETS (ROA) AVG 3Y
-13.16%
RETURN ON ASSETS (ROA) AVG 5Y
-19.94%
RETURN ON ASSETS (ROA) AVG 10Y
-26.94%
RETURN ON ASSETS (ROA) AVG 15Y
-26.44%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-74.05%
CURRENT VS 3Y AVG
-216.08%
CURRENT VS 5Y AVG
-108.58%
CURRENT VS 10Y AVG
-54.34%
CURRENT VS 15Y AVG
-57.25%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-54.57%
vs the sector median at left
Arcturus Therapeutics Holdings Inc.
Market Cap
$416.68M
Return on Assets (ROA)
-41.58%
TTM Avg
-23.89%
3Y Avg
-13.16%
5Y Avg
-19.94%
Market Cap
$415.93M
Return on Assets (ROA)
-30.75%
TTM Avg
-34.79%
3Y Avg
-68.11%
5Y Avg
-68.11%
Market Cap
$410.54M
Return on Assets (ROA)
-71.16%
TTM Avg
-43.23%
3Y Avg
-31.68%
5Y Avg
-18.72%
Market Cap
$408.21M
Return on Assets (ROA)
-41.33%
TTM Avg
-54.52%
3Y Avg
-54.52%
5Y Avg
-54.52%
Market Cap
$406.47M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
Market Cap
$428.16M
Return on Assets (ROA)
-31.15%
TTM Avg
-77.61%
3Y Avg
-57.20%
5Y Avg
-46.24%
Market Cap
$447.43M
Return on Assets (ROA)
-35.10%
TTM Avg
-26.63%
3Y Avg
-37.28%
5Y Avg
-39.51%
Market Cap
$384.23M
Return on Assets (ROA)
-69.44%
TTM Avg
-48.37%
3Y Avg
-55.05%
5Y Avg
-50.20%
Market Cap
$450.64M
Return on Assets (ROA)
-0.01%
TTM Avg
-18.05%
3Y Avg
-43.07%
5Y Avg
-43.70%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $416.68M | -41.58% | -23.89% | -13.16% | -19.94% |
| Carlsmed, Inc. (CARL)vs › | $415.93M | -30.75% | -34.79% | -68.11% | -68.11% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.54M | -71.16% | -43.23% | -31.68% | -18.72% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | -41.33% | -54.52% | -54.52% | -54.52% |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | -23.05% | -30.00% | -27.77% | -27.77% |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | -31.15% | -77.61% | -57.20% | -46.24% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | -35.10% | -26.63% | -37.28% | -39.51% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $384.23M | -69.44% | -48.37% | -55.05% | -50.20% |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | -0.01% | -18.05% | -43.07% | -43.70% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | -83.42% | -53.06% | -45.42% | -42.54% |
ROA
-41.6%
ROE
-54.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -24.26% |
| 2024-12-31 | -23.52% |
| 2023-12-31 | -6.92% |
| 2022-12-31 | 2.08% |
| 2021-12-31 | -51.85% |
| 2020-12-31 | -15.14% |
| 2019-12-31 | -31.64% |
| 2018-12-31 | -49.29% |
| 2017-12-31 | -20.96% |
| 2016-12-31 | -47.71% |
| 2015-12-31 | -27.13% |
| 2014-12-31 | -147.12% |
| 2013-12-31 | -20.96% |
| 2012-12-31 | -785.57% |
| 2011-12-31 | -326.33% |
